FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377029363> ?p ?o ?g. }

• W4377029363 abstract "<b>Abstract ID 26262</b> <b>Poster Board 168</b> The ‘dark side’ of addiction refers to the temporary relief drug-taking provides from the persistent negative emotional state that emerges as a person develops a substance use disorder . In the context of opioid use disorder, negative affect and craving during acute and protracted withdrawal present major barriers to recovery. There is only one non-opioid treatment for acute opioid withdrawal, associated with limited efficacy and serious side effects, and no treatment for protracted withdrawal. KNX100 is a novel, clinical stage small molecule being developed for the treatment of opioid use disorder. KNX100 has an undisclosed pharmacological mechanism of action but has been shown to act in the nucleus accumbens shell to reduce neuronal hyperexcitability and signalling in the pDYN/DYN/KOR receptor pathway during opioid withdrawal in mice, demonstrating highly disease-relevant neural and molecular actions. Moreover, KNX100 reduced the negative affective symptoms of acute naloxone-precipitated oxycodone withdrawal and inhibited the acquisition of withdrawal-induced conditioned-place aversion in mice. Here, the effects of KNX100 on irritability during spontaneous oxycodone withdrawal and cue-induced reinstatement of oxycodone-seeking during abstinence were examined in rats. Prior to oxycodone self-administration, rats were tested for their baseline irritability (aggressive and defensive behaviours on the bottle brush test) and were assessed for baseline somatic symptoms (wet dog shakes). Rats were then trained to self-administer oxycodone for 15h/day for 44-48 days through a surgically implanted intravenous catheter. Each infusion was accompanied by a light+tone. To elicit spontaneous withdrawal, rats underwent 24-hour without a self-administration session. Spontaneous withdrawal symptoms (irritability and somatic symptoms) were assessed during two counterbalanced withdrawal sessions, once treated with vehicle and once with KNX100. For assessment of cue-induced reinstatement, rats underwent a 15-day protracted abstinence period and were tested for reinstatement on day 2 and 15, with rats receiving KNX100 or vehicle prior to reinstatement testing on day 15. KNX100 treatment significantly reduced withdrawal-induced irritability-like behaviour, but not wet dog shakes, in male and female rats. KNX100 markedly inhibited cue-induced reinstatement of drug seeking 15 days into abstinence. These data further indicate KNX100 may alleviate the negative psychological state that emerges during withdrawal and persists into abstinence that contributes to drug craving and relapse and suggest KNX100 may be a viable therapeutic for alleviating the negative affective aspects of acute withdrawal and promoting abstinence. This work was funded by Kinoxis Therapeutics Pty Ltd under a Master Research Services Agreement with the University of Sydney." @default.
• W4377029363 created "2023-05-19" @default.
• W4377029363 creator A5024785432 @default.
• W4377029363 creator A5031782931 @default.
• W4377029363 creator A5049003115 @default.
• W4377029363 creator A5076387239 @default.
• W4377029363 creator A5091974008 @default.
• W4377029363 date "2023-05-18" @default.
• W4377029363 modified "2023-09-26" @default.
• W4377029363 title "A Novel Clinical-stage Small Molecule Targeting the ‘Dark Side’ of Opioid Addiction" @default.
• W4377029363 doi "https://doi.org/10.1124/jpet.122.262620" @default.
• W4377029363 hasPublicationYear "2023" @default.
• W4377029363 type Work @default.
• W4377029363 citedByCount "0" @default.
• W4377029363 crossrefType "proceedings-article" @default.
• W4377029363 hasAuthorship W4377029363A5024785432 @default.
• W4377029363 hasAuthorship W4377029363A5031782931 @default.
• W4377029363 hasAuthorship W4377029363A5049003115 @default.
• W4377029363 hasAuthorship W4377029363A5076387239 @default.
• W4377029363 hasAuthorship W4377029363A5091974008 @default.
• W4377029363 hasBestOaLocation W43770293631 @default.
• W4377029363 hasConcept C118552586 @default.
• W4377029363 hasConcept C126322002 @default.
• W4377029363 hasConcept C151730666 @default.
• W4377029363 hasConcept C15744967 @default.
• W4377029363 hasConcept C170493617 @default.
• W4377029363 hasConcept C2776029756 @default.
• W4377029363 hasConcept C2776552330 @default.
• W4377029363 hasConcept C2777389121 @default.
• W4377029363 hasConcept C2778555786 @default.
• W4377029363 hasConcept C2779343474 @default.
• W4377029363 hasConcept C2779418921 @default.
• W4377029363 hasConcept C2779541405 @default.
• W4377029363 hasConcept C2780820931 @default.
• W4377029363 hasConcept C2781063702 @default.
• W4377029363 hasConcept C42219234 @default.
• W4377029363 hasConcept C48856860 @default.
• W4377029363 hasConcept C558461103 @default.
• W4377029363 hasConcept C71924100 @default.
• W4377029363 hasConcept C86803240 @default.
• W4377029363 hasConcept C98274493 @default.
• W4377029363 hasConceptScore W4377029363C118552586 @default.
• W4377029363 hasConceptScore W4377029363C126322002 @default.
• W4377029363 hasConceptScore W4377029363C151730666 @default.
• W4377029363 hasConceptScore W4377029363C15744967 @default.
• W4377029363 hasConceptScore W4377029363C170493617 @default.
• W4377029363 hasConceptScore W4377029363C2776029756 @default.
• W4377029363 hasConceptScore W4377029363C2776552330 @default.
• W4377029363 hasConceptScore W4377029363C2777389121 @default.
• W4377029363 hasConceptScore W4377029363C2778555786 @default.
• W4377029363 hasConceptScore W4377029363C2779343474 @default.
• W4377029363 hasConceptScore W4377029363C2779418921 @default.
• W4377029363 hasConceptScore W4377029363C2779541405 @default.
• W4377029363 hasConceptScore W4377029363C2780820931 @default.
• W4377029363 hasConceptScore W4377029363C2781063702 @default.
• W4377029363 hasConceptScore W4377029363C42219234 @default.
• W4377029363 hasConceptScore W4377029363C48856860 @default.
• W4377029363 hasConceptScore W4377029363C558461103 @default.
• W4377029363 hasConceptScore W4377029363C71924100 @default.
• W4377029363 hasConceptScore W4377029363C86803240 @default.
• W4377029363 hasConceptScore W4377029363C98274493 @default.
• W4377029363 hasLocation W43770293631 @default.
• W4377029363 hasOpenAccess W4377029363 @default.
• W4377029363 hasPrimaryLocation W43770293631 @default.
• W4377029363 hasRelatedWork W2005929448 @default.
• W4377029363 hasRelatedWork W2019316759 @default.
• W4377029363 hasRelatedWork W2050139747 @default.
• W4377029363 hasRelatedWork W2093721445 @default.
• W4377029363 hasRelatedWork W2170230856 @default.
• W4377029363 hasRelatedWork W2752805271 @default.
• W4377029363 hasRelatedWork W2946104553 @default.
• W4377029363 hasRelatedWork W2988873070 @default.
• W4377029363 hasRelatedWork W3012154540 @default.
• W4377029363 hasRelatedWork W3112505688 @default.
• W4377029363 isParatext "false" @default.
• W4377029363 isRetracted "false" @default.
• W4377029363 workType "article" @default.